Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.76 |
| ▸ | LCK | P06239 | 4/20 | 0.74 |
| ▸ | CLK1 | P49759 | 2/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 6/20 | 0.67 |
| ▸ | RET | P07949 | 4/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | GAK | O14976 | 1/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.64 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.64 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.61 |
| ▸ | KIF5B | P33176 | 2/20 | 0.60 |
| ▸ | FBP1 | P09467 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | FLT4 | P35916 | 1/20 | 0.60 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.60 |
| ▸ | TEK | Q02763 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471854 | 0.92 | KDR (0.69) | EGFRLCKCLK1ABCG2KDR | |
| SCHEMBL18158231 | 0.91 | EGFR (0.83) | EGFRLCKABCG2KDRRET | |
| SCHEMBL4461985 | 0.89 | EGFR (0.60) | EGFRLCKCLK1ABCG2KDR | |
| SCHEMBL4472397 | 0.87 | EGFR (0.58) | EGFRLCKCLK1ABCG2KDR | |
| SCHEMBL4458762 | 0.86 | EGFR (0.57) | EGFRLCKCLK1ABCG2KDR | |
| SCHEMBL5482884 | 0.86 | EGFR (1.00) | EGFRLCKABCG2KDRRET | |
| Hydrochloric Acid SCHEMBL5475745 | 0.85 | EGFR (1.00) | EGFRLCKABCG2KDRRET | |
| SCHEMBL4458635 | 0.84 | SRC (0.76) | EGFRLCKABCG2KDRRET | |
| SCHEMBL4473865 | 0.84 | KDR (0.55) | EGFRLCKCLK1ABCG2KDR | |
| SCHEMBL18158268 | 0.84 | EGFR (0.76) | EGFRLCKCLK1ABCG2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | claimed |
| US-7585869-B2 | Substituted heterocylces for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1636195-A1 | QUINAZOLINES AND PYRIDO[3,4-D]PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004106308-A1 | QUINAZOLINES AND PYRIDO [3,4-D] PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNY | EGFR 166/4885LCK 3238/4885CLK1 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.